Distribution favors metabolically active organs, particularly the kidneys, liver, stomach wall, and intestinal tissues
received advisory/consulting fees and/or other support from Altimmune, AstraZeneca, Bayer, Biomea, Boehringer Ingelheim, Carmot Therapeutics, Cytoki Pharma, Eli Lilly, Intercept, Janssen/Johnson & Johnson, Mannkind, Mediflix, Merck, Metsera, Novo Nordisk, Pharmaventures, Pfizer, Regeneron, Sanofi, Shionogi, Structure Therapeutics, Target RWE, Terns Pharmaceuticals, The Comm Group, Valeritas, WebMD and Zealand Pharma
labs looks like this: Normal range: 200 to 900 pg/mL (some labs use 160 to 950 pg/mL) Optimal range: 400 to 600 pg/mL Elevated: above 900 to 1,000 pg/mL (hypercobalaminemia) These ranges come from sources including UCSF Health and WebMD, though your labs specific cutoffs may differ
The problem appears with multi-dose vials
Reports that do reach the FDA Adverse Event Reporting System (FAERS) for BPC-157 are submitted voluntarily and almost certainly represent a small fraction of actual events, because most users obtain the peptide through channels that never involve a licensed prescriber